Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.

Tytuł:
Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Autorzy:
Czarnowska A; Medical University of Białystok, Poland. .
Brola W; Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Zajkowska O; Faculty of Economic Sciences, University of Warsaw, Poland.
Rusek S; Department of Neurology, Specialist Hospital Ludwika Rydygiera in Krakow, Poland.
Adamczyk-Sowa M; Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.
Kubicka-Bączyk K; Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.
Kalinowska-Łyszczarz A; Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poland.
Kania K; Department of Neurology, Poznan University of Medical Sciences, Poland.
Słowik A; Department of Neurology, Jagiellonian University Medical College, Krakow, Poland.
Wnuk M; Department of Neurology, Jagiellonian University Medical College, Krakow, Poland.
Marona M; Department of Neurology, Jagiellonian University Medical College, Krakow, Poland.
Podlecka-Piętowska A; Department of Neurology, Medical University of Warsaw, Poland.
Nojszewska M; Department of Neurology, Medical University of Warsaw, Poland.
Zakrzewska-Pniewska B; Department of Neurology, Medical University of Warsaw, Poland.
Jasińska E; Collegium Medicum UJK, and Clinical Center, RESMEDICA, Kielce, Poland.
Gołuch K; Clinical Center, RESMEDICA, Kielce, Poland.
Lech B; Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Poland.
Noga M; Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Poland.
Perenc A; Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Poland.
Popiel M; Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Poland.
Lasek-Bal A; Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, Poland.
Puz P; Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, Poland.
Maciejowska K; Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, Poland.
Kucharska-Lipowska M; Department of Neurology, Specialist Hospital in Końskie, Poland.
Lipowski M; Department of Urology, Specialist Hospital in Końskie, Poland.
Kapica-Topczewska K; Medical University of Białystok, Poland.
Chorąży M; Medical University of Białystok, Poland.
Tarasiuk J; Medical University of Białystok, Poland.
Kochanowicz J; Medical University of Białystok, Poland.
Kulikowska J; Medical University of Białystok, Poland.
Wawrzyniak S; Department of Neurology, 10th Military Research Hospital and Polyclinic, Independent Public Healthcare Centre, Bydgoszcz, Poland.
Niezgodzińska-Maciejek A; Department of Neurology, 10th Military Research Hospital and Polyclinic, Independent Public Healthcare Centre, Bydgoszcz, Poland.
Pokryszko-Dragan A; Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
Gruszka E; Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
Budrewicz S; Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
Białek M; Department of Neurology, Regional Specialised Hospital No. 4 in Bytom, Poland.
Kurkowska-Jastrzębska I; 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Kurowska K; 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
Stępień A; Department of Neurology, Military Institute of Medicine, Warsaw, Poland.
Włodek A; Department of Neurology, Masovian Voivodeship Hospital in Siedlce, Poland.
Ptasznik V; Department of Neurology, Specialist Hospital in Pila, Poland.
Pawełczyk M; Department of Neurology and Stroke, Medical University of Lodz, Poland.
Sobolewski P; Department of Neurology and Stroke Unit in Sandomierz, Collegium Medicum, Jan Kochanowski University in Kielce.
Lejmel H; Department of Neurology, The Regional Hospital in Suwalki, Poland.
Strzalińska K; Department of Neurology, The Regional Hospital in Łomża, Poland.
Maciejowski M; KMK Clinical, MS Center, Katowice, Poland.
Tutaj A; Neurology Ward, Provincial Specialist Hospital, Olsztyn, Poland.
Zwiernik J; Neurology Ward, Provincial Specialist Hospital, Olsztyn, Poland; Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland.
Litwin A; Neurology Ward, Provincial Specialist Hospital, Olsztyn, Poland.
Lewańczyk B; Neurology Ward, Provincial Integrated Hospital, Elbląg, Poland.
Paprocka I; Neurology Ward, Provincial Integrated Hospital, Elbląg, Poland.
Zwiernik B; Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland; Clinic of Neurology, University of Warmia and Mazury, Olsztyn, Poland.
Pawlos A; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Warmia and Mazury, Olsztyn, Poland.
Borysowicz A; Department of Neurology, Specialist Hospital Dr Tytus Chałubiński Radom, Poland.
Narożnik A; Department of Neurology, Specialist Hospital Dr Tytus Chałubiński Radom, Poland.
Michałowska A; Neurology Ward, Provincial Specialist Hospital, Olsztyn, Poland.
Nosek K; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Warmia and Mazury, Olsztyn, Poland.
Fudala M; Department of Neurology, Regional Hospital in Skarżysko-Kamienna, Poland.
Milewska-Jędrzejczak M; Department of Neurology and Ischemic Strokes, Medical University of Lodz, Poland.
Kułakowska A; Medical University of Białystok, Poland.
Bartosik-Psujek H; Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Poland.
Źródło:
Neurologia i neurochirurgia polska [Neurol Neurochir Pol] 2021; Vol. 55 (2), pp. 212-222. Date of Electronic Publication: 2021 Apr 15.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2019- : Gdańsk, Poland : Via Medica
Original Publication: Warszawa, Państwowy Zakład Wydawnictw Lekarskich.
MeSH Terms:
COVID-19*
Multiple Sclerosis*/drug therapy
Multiple Sclerosis*/epidemiology
Multiple Sclerosis, Relapsing-Remitting*
Adult ; Female ; Humans ; Immunologic Factors ; Immunosuppressive Agents ; Male ; Poland/epidemiology ; SARS-CoV-2
Contributed Indexing:
Keywords: COVID-19; SARS-CoV-2; disease-modifying therapies; multiple sclerosis
Substance Nomenclature:
0 (Immunologic Factors)
0 (Immunosuppressive Agents)
Entry Date(s):
Date Created: 20210415 Date Completed: 20210504 Latest Revision: 20210504
Update Code:
20240104
DOI:
10.5603/PJNNS.a2021.0031
PMID:
33856686
Czasopismo naukowe
Introduction: The aim of this study was to report the course and outcome of SARS-CoV-2 infection in multiple sclerosis (MS) patients treated with disease-modifying therapies (DMTs) in Poland. A major concern for neurologists worldwide is the course and outcome of SARS-CoV-2 infection in patients with MS treated with different DMTs. Although initial studies do not suggest an unfavourable course of infection in this group of patients, the data is limited.
Materials and Methods: This study included 396 MS patients treated with DMTs and confirmed SARS-CoV-2 infection from 28 Polish MS centres. Information concerning patient demographics, comorbidities, clinical course of MS, current DMT use, as well as symptoms of SARS-CoV-2 infection, need for pharmacotherapy, oxygen therapy, and/or hospitalisation, and short-term outcomes was collected up to 30 January 2021. Additional data about COVID-19 cases in the general population in Poland was obtained from official reports of the Polish Ministry of Health.
Results: There were 114 males (28.8%) and 282 females (71.2%). The median age was 39 years (IQR 13). The great majority of patients with MS exhibited relapsing-remitting course (372 patients; 93.9%). The median EDSS was 2 (SD 1.38), and the mean disease duration was 8.95 (IQR 8) years. Most of the MS patients were treated with dimethyl fumarate (164; 41.41%). Other DMTs were less frequently used: interferon beta (82; 20.70%), glatiramer acetate (42; 10.60%), natalizumab (35;8.84%), teriflunomide (25; 6.31%), ocrelizumab (20; 5.05%), fingolimod (16; 4.04), cladribine (5; 1.26%), mitoxantrone (3; 0.76%), ozanimod (3; 0.76%), and alemtuzumab (1; 0.25%). The overall hospitalisation rate due to COVID-19 in the cohort was 6.81% (27 patients). Only one patient (0.3%) died due to SARS-CoV-2 infection, and three (0.76%) patients were treated with mechanical ventilation; 106 (26.8%) patients had at least one comorbid condition. There were no significant differences in the severity of SARS-CoV-2 infection regarding patient age, duration of the disease, degree of disability (EDSS), lymphocyte count, or type of DMT used.
Conclusions and Clinical Implications: Most MS patients included in this study had a favourable course of SARS-CoV-2 infection. The hospitalisation rate and the mortality rate were not higher in the MS cohort compared to the general Polish population. Continued multicentre data collection is needed to increase the understanding of SARS-CoV-2 infection impact on the course of MS in patients treated with DMTs.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies